Surgical management of colorectal cancer: A review of the literature

Abdel‐Misih, Sherif; Bloomston, Mark

doi:10.1007/s12262-009-0093-5

Cited by 4 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results did not demonstrate any difference in survival between patients undergoing TPE for primary advanced and recurrent colorectal tumors, with a median survival of 25.2 months and 20.2 months, respectively. Other series, however, have demonstrated improved survival for patients with cancers of primary colorectal origin compared with recurrent, with 5-year survival rates ranging from 30 to 77% for primary [ 4 , 5 , 10 , 13 - 16 , 21 , 22 , 37 , 39 , 41 - 44 ] and from 6 to 31% for recurrent disease [ 14 , 21 , 23 , 37 , 41 , 43 - 46 ]. Kecmanovic et al [ 37 ] found median survival rates following TPE for primary and recurrent colorectal tumors were 50 months and 31 months, respectively.…”

Section: Discussionmentioning

confidence: 99%

Retrospective review of pelvic malignancies undergoing total pelvic exenteration

et al. 2012

View full text Add to dashboard Cite

BackgroundIn patients with locally advanced or recurrent pelvic malignancies, total pelvic exenteration (TPE) may be necessary for curative treatment. Despite improvements in mortality rates since TPE was first described, morbidity rates remain high due to the extensive resection and the aggressiveness of these tumors. We have studied the outcomes of TPE surgery performed at our institution.MethodsFifty-three patients with various pelvic pathologies underwent TPE between 2004 and 2010. Patients were divided into two groups based on pathology: colorectal (n = 36) versus non-colorectal (n = 17) malignancies. Demographics, operative reports, pathology reports, periprocedural events, and outcomes were analyzed. Comparison of the two groups was performed using student’s t-test and Fisher’s exact test. Survival curves were constructed using the Kaplan–Meier method and compared using the log rank test.ResultsThe colorectal and non-colorectal groups were similar in demographics, operative times, length of stay, estimated blood loss, and rates of preoperative and intraoperative radiation use. Chemotherapy use was increased in the colorectal group compared with the non-colorectal group (55.6% vs. 23.5%, P = 0.04). Complication rates were similar: 86% in the colorectal group and 76% in the non-colorectal group. In the colorectal group, 27.8% of patients developed perineal abscesses, whereas no patients developed these complications in the non-colorectal group (P = 0.02). No survival difference was seen in primary versus recurrent colorectal tumors; however, within the colorectal group there was a survival advantage when comparing R0 resection to R1 and R2 resection combined. Median survival rates were 27.3 months for R0 resection and 10.7 months for R1 and R2 resection combined. The median survival was 21.4 months for the colorectal group and 6.9 months for the non-colorectal group (P = 0.002).ConclusionsPatients undergoing TPE for colorectal tumors have improved survival when compared with patients undergoing exenteration for pelvic malignancies of other origins. Within the colorectal group, the extent of resection demonstrated a significant survival benefit of an R0 resection compared with R1 and R2 resections. Despite TPE carrying a high morbidity rate, mortality rates have improved and careful patient selection can optimize outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective review of pelvic malignancies undergoing total pelvic exenteration

et al. 2012

View full text Add to dashboard Cite

show abstract

“…4a). This data are of utmost importance since patients that present with CRC will undergo surgery to resect the tumour and in more advanced stages undergo chemotherapy, but still carry the risk of recurrence owing to remaining cells at the tumour resection site that will continue to proliferate 27,28 .…”

Section: Tumour Regression and Recurrence Preventionmentioning

confidence: 99%

Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model

et al. 2016

View full text Add to dashboard Cite

Conventional cancer therapies involve the systemic delivery of anticancer agents that neither discriminate between cancer and normal cells nor eliminate the risk of cancer recurrence. Here, we demonstrate that the combination of gene, drug and phototherapy delivered through a prophylactic hydrogel patch leads, in a colon cancer mouse model, to complete tumour remission when applied to non-resected tumours and to the absence of tumour recurrence when applied following tumour resection. The adhesive hydrogel patch enhanced the stability and provided local delivery of embedded nanoparticles. Spherical gold nanoparticles were used as a first wave of treatment to deliver siRNAs against Kras, a key oncogene driver, and rod-shaped gold nanoparticles mediated the conversion of near-infrared radiation into heat, causing the release of a chemotherapeutic as well as thermally induced cell damage. This local, triple-combination therapy can be adapted to other cancer cell types and to molecular targets associated with disease progression.

show abstract

“…A colectomy (sometimes called a hemicolectomy, partial colectomy, or segmental resection) is conducted to remove a part of the colon, as well as nearby lymph nodes 50,51 . An incision is made in the abdomen and the part of the colon with the cancer along with a small segment of normal colon on either side of the cancer is cut and removed.…”

Section: Open Colectomymentioning

confidence: 99%

“…This is a newer approach to remove a part of the colon and nearby lymph nodes for early stage cancers 50,51 . Instead of making one long incision in the abdomen, the surgeon makes several smaller incisions.…”

Section: Laparoscopic Assisted Colectomymentioning

confidence: 99%

Colorectal Cancer: A Review of Disease Diagnosis, Surgical Intervention and Treatment Procedures

Ramesh¹,

Dsouza²,

Yogish.³

et al. 2018

IRJPS

View full text Add to dashboard Cite

Colorectal cancer, also known as bowel or colon cancer is associated with colon or rectum sections of the intestine. Globally, more than 1 million people are affected by colorectal cancer every year and have been the cause for death in about 715,000 in 2010. As of 2012, it is the second most common cause of cancer in women (9.2% of diagnoses) and the third most common in men (10.0%). It also accounts for the fourth most common cause of cancer death after lung, stomach, and liver cancer. Colorectal cancer develops mostly during aging and as a reason of increasing lifestyle disorders as well as rarely through genetic heredity. Hence, this grows immense interest in the diagnosis, cure, genetic counseling and general awareness about the disease. Surgery, chemotherapy and radiation therapy, either individually or carried out in conjecture, seems to be the best treatment for the disease. Assessment of risk factors is very important in the early detection of the disease. This review aims to compile broadly the available knowledge on the causes of colorectal cancer, the methods for prevention, therapy or treatment of the disease and the guidelines for genetic counseling and general awareness. It also helps in understanding the risk factors in the development of disease.

show abstract

Surgical management of colorectal cancer: A review of the literature

Cited by 4 publications

References 35 publications

Retrospective review of pelvic malignancies undergoing total pelvic exenteration

Retrospective review of pelvic malignancies undergoing total pelvic exenteration

Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model

Colorectal Cancer: A Review of Disease Diagnosis, Surgical Intervention and Treatment Procedures

Contact Info

Product

Resources

About